Table: Sumitomo Pharma 6-MTH group results (IFRS)

Sumitomo Pharma

31/10/2025 06:32

Oct 31 (Reuters)- 
              Sumitomo Pharma Co., Ltd. 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                 6 months ended      6 months ended       Year to 
                Sep 30, 2025        Sep 30, 2024     Mar 31, 2026 
                   LATEST             YEAR-AGO          COMPANY   
                   RESULTS             RESULT          FORECAST   
  Sales            227.12              180.75           429.00    
                 (+25.7 pct)         (+18.4 pct)      (+7.6 pct)  
  Operating         96.16             loss 8.18          98.00    
                                                     (+240.2 pct) 
  Pretax
  Net               98.86            loss 32.23          92.00    
                                                     (+289.3 pct) 
  EPS Basic      248.84 yen        loss 81.12 yen     231.57 yen  
  Ann Div                                NIL              NIL     
  -Q2 Div            NIL                 NIL                      
  -Q4 Div                                NIL              NIL     
 
  NOTE - Sumitomo Pharma Co., Ltd.. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4506.T